Chiglitazar

Chiglitazar
Clinical data
Trade names	Bilessglu
Other names	Carfloglitazar
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid;
CAS Number	743438-45-1;
PubChem CID	71402018;
ChemSpider	57523239;
UNII	E6EJV1J6Y0;
ChEMBL	ChEMBL4650349;
CompTox Dashboard (EPA)	DTXSID00225352 ;
Chemical and physical data
Formula	C36H29FN2O4
Molar mass	572.636 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F;
	InChI InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1; Key:QNLWMPLUWMWDMQ-YTTGMZPUSA-N;

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.^[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.^[2]

References[edit]

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.